Pharma: A setback in cholesterol drug development raises concerns about the future of a multibillion-dollar market.
Novartis' setback heightens the competition for Amgen and Eli Lilly as they strive to convert lower Lp(a) levels into reduced heart attack and stroke rates. The pressure is on—who will lead the way in heart health innovation? #CardioHealth #PharmaRace
What's Your Reaction?
Like
0
Dislike
0
Love
0
Funny
0
Angry
0
Sad
0
Wow
0
